Le réseau des PCN vous invite à une série de webinaires d’information entre mi-avril et fin mai pour le lancement du programme de travail 2025 d’Horizon Europe.
Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)
2 000 000
HORIZON Coordination and Support Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-DISEASE-03
Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential
50 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-TOOL-05
Boosting the translation of biotech research into innovative health therapies
80 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-DISEASE-07
Tackling high-burden for patients and under-researched medical conditions
30 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-TOOL-03
Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)
50 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-IND-02
Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices
4 000 000
HORIZON Coordination and Support Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-DISEASE-01
Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections
45 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-DISEASE-04
Leveraging artificial intelligence for pandemic preparedness and response
35 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-CARE-01
End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)
40 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-TOOL-02
Advancing cell secretome-based therapies
40 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-TOOL-01
Enhancing cell therapies with genomic techniques
50 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-IND-01
Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)
40 000 000
HORIZON Innovation Actions
22/05/2025
16/09/2025
102 jours
HORIZON-HLTH-2025-01-DISEASE-06
Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)
Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)
Clôture :16/09/2025
Clôture (2nde étape) :
HORIZON-HLTH-2025-03-two-stage
Cluster 1 - Health (Two stage - 2025)
Topic(s)
Title
Budget disponible (€)
Action(s)
Ouverture
Clôture
Clôture (2nde étape)
HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage
Advancing knowledge on the impacts of micro- and nanoplastics on human health
40 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
16/04/2026
102 jours
HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage
The impact of pollution on the development and progression of brain diseases and disorders
40 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
16/04/2026
102 jours
HORIZON-HLTH-2025-03-DISEASE-02-two-stage
Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders
50 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
16/04/2026
102 jours
HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage
Improving the quality of life of persons with intellectual disabilities and their families
40 000 000
HORIZON Research and Innovation Actions
22/05/2025
16/09/2025
16/04/2026
102 jours
HORIZON-HLTH-2025-03-IND-03-two-stage
Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices